PTPRC and neoplasm: Confocal microscopy of tumor sections revealed that even though all the Dexo vaccines tested were capable of recruiting CD45+ hematopoietic cells and, especially, CD3+ cells at the tumor site as compared to saline treatment, Dexo(B16 + pIC) vaccination induced greater hematopoietic recruitment and, most importantly, infiltration of the tumor mass by lymphocytes (Fig. 6, top).